CRXX CombinatoRx, Incorporated

[greencat]

CRXX is amking a stair pattern and has filled the gap. I look for it to tske out the 1.50 area eaisly.

CRXX Chart


CombinatoRx, Incorporated
245 First Street
Third Floor
Cambridge, MA 02142
United States - Map
Phone: 617-301-7000
Fax: 617-301-7010
Web Site: CombinatoRx

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 73


BUSINESS SUMMARY
CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The company’s products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. The company has a collaboration and licensing agreement with Clinical Data Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. CombinatoRx, Incorporated also has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charley’s Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts.

[greencat]

CRXX is making a nice move and will probably challenge old hihs at $2.60.

CRXX Chart


CombinatoRx, Incorporated
245 First Street
Third Floor
Cambridge, MA 02142
United States - Map
Phone: 617-301-7000
Fax: 617-301-7010
Web Site: CombinatoRx

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 73


BUSINESS SUMMARY
CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The company’s products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. The company has a collaboration and licensing agreement with Clinical Data Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. CombinatoRx, Incorporated also has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charley’s Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts.[/QUOTE]